Changing the Guidelines for CLL Clinical Endpoints

Published in the Journal of Clinical Oncology,  Dr. Kipps and several other prominent CLL experts reviewed the guidelines for assessing clinical outcomes in relation to ‘new’ novel targeted agents.

Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia

miR-125b and CLL

The downregulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state.

MiR-125b-1 maps at 11q24, a chromosomal region close to the epicenter of 11q23 deletions in chronic lymphocytic leukemias (CLLs). Our results establish that both aggressive and indolent CLL patients show reduced expression of miR-125b. Overexpression of miR-125b in CLL-derived cell lines resulted in the repression of many transcripts encoding enzymes implicated in cell metabolism.

ROR1 is expressed in human breast cancer

The BCRF Lab has just published “ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.”

Receptor-tyrosine-kinase-like orphan receptor 1 (ROR1) is expressed during embryogenesis and by certain leukemias, but not by normal adult tissues. Here we show that the neoplastic cells of many human breast cancers express the ROR1 protein and high-level expression of ROR1 in breast adenocarcinoma was associated with aggressive disease.

Personalized Care

UC San Diego: My Answer To Cancer

With My Answer To Cancer, we already have some of the top scientists and doctors in the nation committed to the fight against cancer. Now, we need you. This initiative has the power to transform cancer care, but it won’t happen without your support.

Personalized Cancer Care. Targeting Cancer cells is the future and we need your help. See Why and Donate Today…